Can We Define High-risk DAPT Patients in USA Practice? - ppt download
XIENCE Stent: Protecting Patients with Short DAPT Needs | Abbott
Primary Results of the EVOLVE Short DAPT Study | Circulation: Cardiovascular Interventions
Antiplatelet Therapy in High-Bleeding Risk Patients Undergoing PCI: Walking a Tightrope
EVOLVE Short DAPT in Print: P2Y12 Decisions Can Safely Be Made Case-by-Case | tctmd.com
SYNERGY™ Clinical Program - Short DAPT - Boston Scientific
Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention - ScienceDirect
EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent | tctmd.com
Complex Coronary Cases - ppt download
For the FITs | Antiplatelet Therapy For High Bleeding Risk Patients Undergoing PCI - American College of Cardiology
Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives | SpringerLink
Ajay Kirtane, EVOLVE SHORT DAPT WEB - Cardiovascular News
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation | JACC: Cardiovascular Interventions
PDF) Evolving Concepts in Post-PCI Antiplatelets Therapy
Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT | tctmd.com
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
Synergy: Short DAPT Study - ppt download
SYNERGY™ Clinical Program - Short DAPT - Boston Scientific
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
EVOLVE Short DAPT
Evolving Concepts in Post-PCI Antiplatelets Therapy - Kartik Pandurang Jadhav, Pankaj V. Jariwala, 2020
